KRAS and non-small cell lung carcinoma: YTHDF1 deficiency renders tumors resistant to cisplatin dependent chemotherapy in vivo, suggesting that KRAS mutations along with YTHDF1 mutations, or expression level, should be simultaneously considered to predict the efficacy of NSCLC therapies.